Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Trial of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes

12. oktober 2015 oppdatert av: NewChapter, Inc.

A Randomized, Double-blind, Placebo-controlled Trial to Assess Efficacy and Tolerability of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes

This is a multi-center, randomized, double-blind, placebo-controlled study in approximately 104 subjects (52 per group) to evaluate the effectiveness of an herb and mineral combination product on fasting serum glucose levels in subjects with impaired fasting glucose. The study consists of 5 visits: a Screening visit, followed by a Baseline visit (at which eligible subjects will be randomized to product to consume throughout the 12-week supplementation period), followed by Supplementation period visits at 3, 6 and 12 weeks after baseline.

Studieoversikt

Detaljert beskrivelse

The target population of this clinical trial is otherwise healthy, pre-diabetic adults who present with impaired fasting glucose.

Studietype

Intervensjonell

Registrering (Faktiske)

104

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Illinois
      • Chicago, Illinois, Forente stater, 60610
        • Radiant Research
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40509
        • Central Kentucky Research Associates
    • Michigan
      • Bingham Farms, Michigan, Forente stater, 48025
        • Quest Research Institute
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45249
        • Radiant Research
      • Dayton, Ohio, Forente stater, 45439
        • Providence Health Partners Center for Clinical Research
    • South Carolina
      • Greer, South Carolina, Forente stater, 29651
        • Mountain View Clinical Research

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Be male or female, at least 18 years of age
  • If age ≥45 years, must have a body mass index ≥ 25 kg/m2
  • If age <45 years, must have a body mass index ≥ 25 kg/m2 AND present with at least one additional risk factors for developing diabetes.
  • Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (women only)
  • Be able to understand the nature and purpose of the study including potential risks and side effects
  • Be willing to consent to study participation and to comply with study requirements
  • Have a finger stick fasting blood glucose between 105 and 140 mg/dL and a serum fasting glucose between 100 and 125 mg/dL, measured at screening

Exclusion Criteria:

  • Have diabetes (type I or II) or an HBA1c measurement >6.5% at any time in the past or at the screening visit
  • Have been taking within 2 weeks of screening any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose metabolism
  • Have been taking within 4 weeks of screening any prescription or over-the-counter (OTC) medication that significantly affects glucose metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors), systemic corticosteroids
  • Daily use of non-steroidal anti-inflammatory drugs (NSAIDS) (daily baby aspirin use and continuous use of NSAIDS for 3 days or less for acute aches and pains are acceptable)
  • Any co-morbidity or treatment that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
  • Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
  • Eating disorder
  • Polycystic ovary syndrome
  • Known allergies or intolerance to any substance in the study product
  • Are pregnant or breastfeeding women
  • History of alcohol, drug, or medication abuse
  • Have participated in another study with any investigational product within 1 month of screening
  • Had a recent (<3 months) gastrointestinal surgery or any planned surgery during the clinical study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: herb and mineral combination product
Subjects will consume 3 herb and mineral combination product softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period.
herb and mineral product containing cinnamon, turmeric and holy basil
Placebo komparator: placebo
Subjects will consume 3 softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period
Placebo of herb and mineral product containing cinnamon, turmeric and holy basil

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in fasting blood glucose
Tidsramme: Day 84
Fasting glucose will be measured on serum samples obtained at screening (to be used as baseline value) and at day 84
Day 84

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in fasting serum glucose
Tidsramme: Day 42
Fasting glucose will be measured on serum samples obtained at screening (to be used as baseline value) and at day 42
Day 42
Change from Baseline in fasting blood glucose
Tidsramme: Day 21
Fasting glucose will be measured on serum samples obtained at screening (to be used as baseline value) and at day 21
Day 21
Change from Baseline in HbA1c
Tidsramme: Day 84
Glycosylated hemoglobin (HbA1c) will be measured on whole blood samples obtained at screening and at day 84.
Day 84
Change from Baseline in fasting lipids
Tidsramme: Day 84
Total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triglycerides will be measured on serum samples obtained at screening and at day 84 using a standard lipid panel.
Day 84
Change from Baseline in fasting lipids
Tidsramme: Day 42
Total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triglycerides will be measured on serum samples obtained at screening and at day 42 using a standard lipid panel.
Day 42
Change from Baseline in fasting lipids
Tidsramme: Day 21
Total cholesterol, high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, and triglycerides will be measured on serum samples obtained at screening and at day 21 using a standard lipid panel.
Day 21
Change from Baseline in BMI
Tidsramme: Day 84
Body mass index
Day 84
Change from Baseline in waist-to-hip ratio
Tidsramme: Day 84
Day 84

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. februar 2013

Primær fullføring (Faktiske)

1. juni 2015

Studiet fullført (Faktiske)

1. juni 2015

Datoer for studieregistrering

Først innsendt

7. april 2014

Først innsendt som oppfylte QC-kriteriene

20. mai 2014

Først lagt ut (Anslag)

23. mai 2014

Oppdateringer av studieposter

Sist oppdatering lagt ut (Anslag)

14. oktober 2015

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. oktober 2015

Sist bekreftet

1. oktober 2015

Mer informasjon

Begreper knyttet til denne studien

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på herb and mineral combination product

3
Abonnere